Ignite Creation Date:
2024-05-06 @ 7:29 PM
Last Modification Date:
2024-10-26 @ 3:07 PM
Study NCT ID:
NCT06022757
Status:
RECRUITING
Last Update Posted:
2024-02-23
First Post:
2023-08-17
Brief Title:
Study of XNW5004 Tablet in Combination With KEYTRUDA Pembrolizumab in Subjects With Advanced Solid Tumors Who Failed Standard Treatments KEYNOTE F19
Sponsor:
Organization:
Evopoint Biosciences Inc
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
204
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE1 |
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: